Treatment of Hemophilia A
Health ConditionsBlood DisordersHemophilia

Hemophilia A Treatment: A Complete Guide

Hemophilia A Treatment: A Complete Guide
iStock
By
and
Updated on October 31, 2024
by

Hemophilia is a complex disease that requires care from medical providers who are experienced in treating it.

The symptoms of hemophilia — bleeding and bruising — are caused by having a low level of clotting factors in the blood. Therefore, people with hemophilia need to replace those factors so that their blood is able to clot appropriately.

There are multiple treatments, medications, and other supportive therapies that can mitigate the symptoms of hemophilia A.

9 Symptoms of Hemophilia A

Keep your eyes open for these telling signs of Hemophilia A.
9 Symptoms of Hemophilia A

Next up video playing in 10 seconds

Medication

The main focus of hemophilia treatment is to replace clotting factors in the blood. There are two basic types of clotting factor replacements: 

  • Plasma-derived factor concentrates, derived from donated human plasma
  • Recombinant factor concentrates developed from culturing cells

Both of these treatments are given by injection under a person’s skin or directly into a vein.

People can receive these concentrated treatments for bleeding that has already occurred, or to prevent future bleeding. Receiving them to prevent future bleeding incidents is called prophylactic care because it is preventive. Providing treatment to stop bleeding that is already occurring is called episodic treatment.

People can administer clotting factor replacements to themselves or have a family member or other caregiver administer them.

Medications
How it Works

Plasma-derived factor concentrates

These are blood clotting factors that come from plasma donated by other people.

Recombinant factor concentrates

These concentrates are made by culturing cells and then manipulating the DNA in those cells to isolate the blood factor needed.

Monoclonal antibodies

These drugs function by working in place of natural blood clotting factors.

Antifibrinolytics

These are clot-promoting drugs that prevent the breakdown of a protein called fibrin.

Fibrin sealants

These medicines can be put directly on a wound to help the blood clot.

Gene therapy

This is a onetime therapy administered by intravenous infusion. It has a viral vector that contains a gene for the clotting factor 8.

Bypassing agents

These agents do not replace the missing factors. Instead they help the body form a normal clot by bypassing the factors that are blocked by these inhibitors.

Non-factor treatment

This treatment works by reducing the amount of a naturally occurring anticoagulation protein, called tissue factor pathway inhibitor.

Plasma-Derived Factor Concentrates

Plasma-derived factor concentrates are blood clotting factors that come from plasma donated by other people.

Plasma is the liquid part of blood, which contains many proteins, including antibodies and clotting factors. It is first separated from the red blood cells, then it goes through additional processing to break it down into its different components, including clotting factors. These isolated clotting factors can then be freeze-dried for use in therapeutic treatments.

Plasma and its components are tested for bacteria and viruses. The blood product is further treated to kill any pathogens (disease-causing microorganisms) that might still be present.

These drugs include:

  • Antihemophilic factor (Hemofil-M)
  • Antihemophilic factor and von Willebrand factor complex (Alphanate)

Recombinant Factor Concentrates

Recombinant factor concentrates are developed by culturing cells and then manipulating the DNA in those cells to isolate the blood factor needed.

 This method allows scientists to create a key factor used to treat hemophilia A called factor 8 concentrate. This factor can be created without plasma or albumin, another protein present in blood plasma. As a result, it’s unlikely the product will contain any viruses.

These drugs include:

Monoclonal Antibodies

The injection drug emicizumab-kxwh (Hemlibra) functions by working in the place of natural blood clotting factors. It is used to prevent bleeding episodes or to lessen their occurance.

Antifibrinolytics

Antifibrinolytics are clot-promoting drugs that prevent the breakdown of a protein called fibrin.

  • Desmopressin acetate (DDAVP) is a synthetic chemical that is administered by a nasal spray. It resembles a hormone made by the pituitary gland called arginine vasopressin.

DDAVP causes the body to produce more factor 8. People with mild hemophilia A can use DDAVP, but it is less useful for those with more severe disease.

  • Epsilon aminocaproic acid (Amicar) is given intravenously or orally in pill or liquid form to stop blood clots from breaking down.

It is not given on a regular basis, but it has been used to help control bleeding when a person with hemophilia A undergoes a dental procedure.

Fibrin Sealants

Medicines called fibrin sealants can be put directly on a wound to help the blood clot.

Minor cuts or bleeding from procedures, such as dental procedures, should also receive basic first aid care, but these sealants can assist with healing.

Gene Therapy

In 2023, the U.S. Food and Drug Administration (FDA) approved the first gene therapy for severe hemophilia A. Known as valoctocogene roxaparvovec-rvox (Roctavian), this gene therapy is only approved for adults. It is a onetime gene therapy administered by intravenous infusion. It has a viral vector that contains a gene for the clotting factor 8.



Bypassing Agents

Some people with hemophilia can have inhibitors that prevent clotting factor concentrates from working. The body may identify this factor as a foreign substance and try to destroy it.

In these cases, a physician may use a bypass agent to help the patient with clotting.

These agents do not replace the missing factors. Instead they help the body form a normal clot by bypassing the factors that are blocked by these inhibitors.

These medications include:

  • Anti-inhibitor coagulant complex (Feiba)
  • Coagulation factor 7a, recombinant (NovoSeven RT, SEVENFACT)

Non-Factor Treatment

In October 2024, the FDA approved the new drug marstacimab-hncq (Hympavzi). It is the first non-factor treatment, and it works by reducing the amount of a naturally occurring anticoagulation protein, called tissue factor pathway inhibitor.

As a result, the body generates an enzyme critical in blood clotting called thrombin. The drug is approved for people over age 12 with hemophilia A without factor 8 inhibitors or hemophilia B without factor 9 inhibitors (neutralizing antibodies).

Delivery Devices to Reduce Injections

Since hemophilia treatment can involve so many injections, some people opt to use a central venous access device (CVAD).

These are medical devices implanted under a person’s skin to provide frequent injections. The most common type is a port-a-cath, but other types of CVADs exist.

Port-a-caths remove the need for a clinician to repeatedly find a vein for injections, so they are particularly helpful in children. But the risks of port-a-caths include infection and blood clots, including thrombosis (a large blood clot).

Rehabilitation and Therapy

People with hemophilia may experience pain in their joints from internal bleeding. Sometimes the joints can become permanently damaged due to the bleeding, which is called hemophilic arthropathy.

Physical therapy can help strengthen a person’s muscles to reduce this pain and help preserve joint function. A physical therapist has many options for helping to preserve joint function, including manual therapy, corrective exercises, orthotics, braces, or splinting. They can also use transcutaneous electrical nerve stimulation, where a low-voltage electrical current is passed through the skin to stimulate the nerves.

Complementary and Integrative Approaches

For some people, complementary therapies can help with the pain and stress of dealing with hemophilia A. These therapies can include acupressure, acupuncture, yoga, and reflexology, among others.

Pain Management 

People with pain due to hemophilia A have multiple options for pain management. They can try the PRICE method, an acronym for Protect, Rest, Ice, Compression, and Elevation, to help treat an injury.

They can also often take certain over-the-counter pain relievers, such as acetaminophen (Tylenol), but they should avoid ibuprofen (Advil) and aspirin, due to bleeding risks. They may also be able to take non-opioid pain medications such as a COX-inhibitor (Celebrex).

Mental Health Treatment

Dealing with a diagnosis of hemophilia A can impact emotional health, and many people with a chronic illness also have a mental health disorder such as depression or anxiety.

The National Hemophilia Foundation has recommendations for people seeking mental health support, including informational videos and links to groups such as the Bleeding Disorders Substance Abuse and Access Coalition.

They also recommend finding and seeking support from local hemophilia treatment centers and chapters.

Certain other treatments, including cognitive behavioral therapy, mindfulness, and acceptance therapy, can also help.

Questions to Ask Your Doctor

  • What medications are best to help with the aches and pains associated with hemophilia A? 
  • Should I consider getting a central venous access device, or CVAD, in order to minimize the amount of injections I will need? 
  • Should I consider taking the newly FDA-approved non-factor treatment?

The Takeaway

  • Hemophilia A is a complex disease, but there are multiple treatment options for people with the condition.
  • Most hemophilia treatments focus on replacing or mimicking key factors that help with blood clotting.
  • There are also supportive and complementary therapies that can help with the stress and pain associated with living with hemophilia A.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network

Sanjai Sinha, MD

Medical Reviewer
Castle Connolly Top Doctor
Sanjai Sinha, MD, is a board-certified internal medicine physician and an assistant professor of clinical medicine and the director of the care management program at Weill Cornell Medical College. Helping patients understand health information and make informed decisions, and communicating health topics effectively both in person and through patient educational content, is a challenge that animates his daily life, and something he is always working to improve.

Dr. Sinha did his undergraduate training at the University of California in Berkeley, where he graduated magna cum laude. He earned his medical degree at the Albert Einstein College of Medicine in New York City in 1998 and completed his internship and residency training at the New York University School of Medicine in 2001. Subsequently, he worked with the Department of Veterans Affairs from 2001 to 2012 and held faculty appointments at both the Mount Sinai School of Medicine and Columbia University College of Physicians and Surgeons.

In 2006, he won the VISN3 Network Director Award for Public Service and a commendation from the secretary of Veterans Affairs for his relief work after Hurricane Katrina. He joined Weill Cornell Medical College in 2012, where he is an assistant professor of clinical medicine and the director of the care management program, as well as a practicing physician.

In addition to his work for Everyday Health, Sinha has written for various publications, including Sharecare and Drugs.com; published numerous papers in peer-reviewed medical journals, such as the Journal of General Internal Medicine; and presented at national conferences on many healthcare delivery topics. He is a fellow of the American College of Physicians.
See full bio
Tara Haelle

Tara Haelle

Author
With two decades of reporting experience under her belt, Tara Haelle has written for a range of publications, including National Geographic, The New York Times, Texas Monthly, Science News, NPR, Washington Post, Scientific American, Politico, Parents, WebMD, Self, O Magazine, and Wired.

She specializes in writing about public health and medical research, particularly vaccines, infectious disease, maternal and pediatric health, mental health, healthcare disparities, LGBTQIA+ health, misinformation, and parenting. Her trade work covering medical research and medical conferences has appeared in MDEdge, Medscape/WebMD, and Haymarket titles.

A former Forbes and Medium contributor, Haelle regularly blogs at the Association of Health Journalists, where she is the Infectious Disease Beat Leader and former Medical Studies Beat Leader, providing resources and training on responsible journalistic coverage of infectious disease and medical research. Her monthly blog at Science and the Sea, from the University of Texas Marine Science Institute, highlights short stories about marine life.

Haelle’s Vaccination Investigation: The History and Science of Vaccines is a starred Kirkus book. She co-authored The Informed Parent: A Science-Based Resource for Your Child’s First Four Years, and she has written nearly a dozen children’s nonfiction science books. As a professional speaker, she has spoken about vaccine hesitancy at TEDx Oslo and has delivered national and international keynotes, webinars and grand rounds on vaccines and vaccine hesitancy, parenting, understanding medical research, storytelling, and mental health.

Haelle received her master’s in photojournalism from the University of Texas at Austin, and her images have appeared in NPR, Texas Monthly, Science News, the Fort Worth Star-Telegram, Chicago Sun-Times and Women’s Wear Daily. An avid traveler, she has backpacked, hiked, train-hopped, sky-dived, spelunked, scuba-dived and motorbiked through dozens of countries. She lives in Texas with her husband and two sons, four dogs, and 15 pet rats, give or take.
See full bio

Gillian Mohney

Author

Gillian Mohney has spent over a decade covering health and wellness for national outlets. She previously worked at ABC News and Healthline. She has a master's degree from the Columbia University Graduate School of Journalism.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Treatment of Hemophilia. Centers for Disease Control and Prevention (CDC). May 15, 2024.
  2. Products Licensed in the U.S. National Bleeding Disorders Foundation.
  3. Antihemophilic Factor (Intravenous Route). Mayo Clinic. January 31, 2024.
  4. FDA Approves Emicizumab-kxwh for Hemophilia A With or Without Factor VIII Inhibitors. U.S. Food and Drug Administration. October 2018.
  5. Antifibrinolytic Agent. National Cancer Institute. 2024.
  6. Desmopressin Acetate. PubChem.
  7. Aminocaproic Acid. MedlinePlus. October 15, 2023.
  8. Aminocaproic Acid (Oral Route). Mayo Clinic. January 31, 2024.
  9. Hemophilia. Mayo Clinic.
  10. First Gene Therapy for Adults With Severe Hemophilia A. U.S. Food and Drug Administration. June 29, 2023.
  11. Testing for Inhibitors and Hemophilia. Centers for Disease Control and Prevention. May 2024.
  12. FDA Approves New Treatment for Hemophilia A or B. U.S. Food and Drug Administration. October 2024.
  13. Port-a-cath. National Cancer Institute.
  14. Law BM. Parents’ Guide to CVADs. HEMAWARE. August 2020.
  15. Joint Protection. National Bleeding Disorders Foundation.
  16. Pain Management for Adults. National Bleeding Disorders Foundation.
  17. Mental Health Resource List. National Hemophilia Foundation.